LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Blueprint Medicines Corp

Geschlossen

BrancheGesundheitswesen

127.83 -0.02

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

127.51

Max

128.01

Schlüsselkennzahlen

By Trading Economics

Einkommen

50M

496K

Verkäufe

3M

149M

EPS

-0.294

Gewinnspanne

0.332

Angestellte

682

EBITDA

-14M

-41M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+1.35% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.5B

8.3B

Vorheriger Eröffnungskurs

127.85

Vorheriger Schlusskurs

127.83

Nachrichtenstimmung

By Acuity

32%

68%

87 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Blueprint Medicines Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juni 2025, 09:17 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2. Juni 2025, 05:31 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

2. Juni 2025, 13:50 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2. Juni 2025, 10:50 UTC

Akquisitionen, Fusionen, Übernahmen

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2. Juni 2025, 10:05 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2. Juni 2025, 05:06 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2. Juni 2025, 05:06 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2. Juni 2025, 05:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2. Juni 2025, 05:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2. Juni 2025, 05:04 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2. Juni 2025, 05:04 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2. Juni 2025, 05:03 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Blueprint Medicines Corporation

2. Juni 2025, 05:02 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Acquire Blueprint Medicines Corporation

Peer-Vergleich

Kursveränderung

Blueprint Medicines Corp Prognose

Kursziel

By TipRanks

1.35% Vorteil

12-Monats-Prognose

Durchschnitt 129.63 USD  1.35%

Hoch 143 USD

Tief 105 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Blueprint Medicines Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

20 ratings

4

Buy

16

Halten

0

Sell

Technischer Score

By Trading Central

87.66 / 99.25Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

87 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.